Claims
- 1. A compound of formula (I):
- 2. The compound of claim 1 wherein:
R1 is
(a) phenyl or heteroaryl selected from furanyl, thienyl, pyridyl, pyrrolyl, imidazolyl and benzofuranyl optionally substituted with one to two R3, (b) R6(CH2)mO—, (c) R6OCH2—, (d) R6(CH2)mNH—, (e) R6(CH2)p(CH═CH)m—, (f) C1-6alkyl, optionally partially of fully halogenated and optionally substituted with one to two R9, (g) C1-8alkoxy, optionally partially of fully halogenated and optionally substituted with one to two R9, (h) C1-6alkylthio, (i) —N(R4)(R5), or (j) —C(O)NHR′, wherein R′ is R6, pyridyl or —CH3, R2 is
(a) C1-6alkyl, optionally substituted with R10, (b) C1-6alkoxy, optionally substituted with R10, (c) C1-6alkylamino, optionally substituted with R10, (d) heterocyclyl selected from from 1-piperidinyl, 1-piperazinyl, 4-morpholinyl, 1-pyrrolidinyl, 1,4-diazacycloheptan-1-yl, 1-azepanyl, 2,5-diazabicyclo[2.2.1]heptan-2-yl, oxazepan-4-yl and 4-thiomorpholino and is optionally substituted with one to three R7, (e) heterocyclylCH2O— wherein the heterocyclyl is selected from 1-piperidinyl, 1-piperazinyl, 4-morpholinyl and 1-pyrrolidinyl, optionally substituted with C1-6alkyl, or (f) —N(R4)(R5); R3 is chosen from C1-6alkyl, C1-6alkoxy, hydroxyC1-6alkyl, halogen, —CN, —CO2H, —CO2C1-6alkyl, —S(O)nC1-6alkyl, —NO2, —OH, —CF3, —N(R4)(R5), —NHC(O)NHC1-6alkyl, —C(O)N(R4)(R5) and phenyl optionally substituted with halogen, C1-6alkyl, —CN or C1-6alkoxy; R4 and R5 are independently selected from H, C1-6alkyl, —C(O)C1-6alkyl, pyridyl, benzyl, piperidinyl and phenylethyl; R6 is a phenyl group optionally substituted with one or two groups selected from Cl, F, C1-6alkyl, —CN, CO2C1-6alkyl, C(O)NR4R5, —SO2NH2, —NO2, —OH, —NH2, —CF3 and C1-6alkoxy or R6 is C3-6cycloalkyl, —CH2OH, naphthalene-2-yl, naphthalene-1-yl or 2-thienyl; R7 is selected from —OH, —CN, oxo, —CO2C1-6alkyl, —C(O)N(R4)(R5), —N(R4)(R5), —CH2N(R4)(R5), CH2OH, C1-6alkyl, —C(O)C1-6alkylN(R4)(R5), —NHC(O)N(R4)(R5), —S(O)nC1-6alkyl, H2NCH(R8)C(O)—, HO(CH2)mCH2CH(NH2)C(O)—, HOCH(R6)CH2NH— and —C(O)heterocyclyl, wherein said heterocyclyl is selected from piperidinyl, piperazinyl, morpholinyl and pyrrolidinyl, or R7 is 2-hydroxyethylamino, methylcarbamimidoyl, hydroxyimino, hydrozinocarbonyl, sulfamoyl, methanesulfonylamino, methylsulfonylhydrazino, 2-hydroxypropylamino, 2,3-dihydroxypropylamino, 2-hydroxy-1-methylethylamino, carbamoylmethylamino, N′-phenylhydrazinocarbonyl or toluene-4-sulfonylamino; R8 is selected from C1-6alkyl, —(CH2)1-4NH2, phenyl or benzyl; R9 is —OH; R10 is selected from —OH, —N(R4)(R5), C1-6alkoxy and heteroaryl selected from furanyl, thienyl and pyridyl; m is 0 or 1; n is 0, 1 or 2; and p is 0, 1, 2 or 3; and pharmaceutically acceptable salts, esters, tautomers, individual isomers, and mixtures of isomers thereof; with the proviso that if R1 is phenyl or heteroaryl, C1-6alkyl, —CF3, —C(O)NR4R5 or heterocyclyl, then R2 is not C1-6alkyl, phenyl, heteroaryl, —CF3, or H.
- 3. The compound of claim 1 wherein:
R1 is
(a) phenyl or heteroaryl selected from furanyl, thienyl and pyridyl, optionally substituted with one to two R3, (b) R6(CH2)mO—, (c) R6OCH2—, (d) R6(CH2)mNH—, (e) R6(CH2)p(CH═CH)m—, (f) C1-6alkyl, (g) C1-6alkylOH, (h) —CF3, (i) C1-8alkoxy, (j) —OC1-6alkylOH, (k) C1-8alkylthio, (l) —N(R4)(R5), or (m)-C(O)NHR′, wherein R′ is R6, pyridyl or —CH3; R2 is beterocyclyl wherein said heterocycle is selected from 1-piperidinyl, 1-piperazinyl, 4-morpholinyl, 1-azepanyl, 1-pyrrolidinyl, 1,4-diazacycloheptan-1-yl, 1-azepanyl 2,5-diazabicyclo[2.2.1]heptan-2-yl, oxazepan-4-yl and 4-thiomorpholino and is optionally substituted with one to three R7, R3 is chosen from C1-6alkyl, C1-6alkoxy, hydroxyC1-6alkyl, halogen, —CN, —CO2H, —CO2C1-6alkyl, —S(O)nC1-6alkyl, —NO2, —OH, —CF3, —N(R4)(R5), —NHC(O)NHC1-6alkyl, —C(O)N(R4)(R5) and phenyl optionally substituted with halogen, C1-6alkyl, —CN or C1-6alkoxy; R4 and R5 are independently selected from H, C1-6alkyl, —C(O)C1-6alkyl, pyridyl, benzyl, piperidinyl and phenylethyl; R6 is a phenyl group optionally substituted with one or two groups selected from Cl, F, C1-6alkyl, —CN, —CO2C1-6alkyl, —C(O)NR4R5, —SO2NH2, —NO2, —OH, —NH2, —CF3 and C1-6alkoxy, or R6 is C36cycloalkyl, —CH2OH, naphthalene-2-yl, naphthalene-1-yl or 2-thienyl; R7 is selected from —OH, —CN, oxo, —CO2C1-6alkyl, —CO2H, —C(O)N(R4)(R5), —N(R4)(R5), —CH2N(R4)(R5), —CH2OH, C1-6alkyl, —C(O)C1-6alkylN(R4)(R5), —NHC(O)N(R4)(R5), —S(O)nC1-6alkyl, phenyl, pyridyl, H2NCH(R9)C(O)—, HO(CH2)mCH2CH(NH2)C(O)—, HOCH(R6)CH2NH—, R6CH2CH(OH)CH2NH—, R6OCH2CH(OH)CH2NH— and —C(O)heterocyclyl, wherein said heterocyclyl is selected from piperidinyl, piperazinyl, morpholinyl and pyrrolidinyl, or R7 is 2-hydroxyethylamino, methylcarbamimidoyl, hydroxyimino, hydrozinocarbonyl, sulfamoyl, methanesulfonylamino, methylsulfonylhydrazino, 2-hydroxypropylamino, 2,3-dihydroxypropylamino, 2-hydroxy-1-methylethylamino, carbamoylmethylamino, N′-phenylhydrazinocarbonyl or toluene-4-sulfonylamino; R8 is selected from C1-6alkyl, —(CH2)1-4NH2, phenyl or benzyl; m is 0 or 1; n is 0, 1 or 2; and p is 0, 1, 2 or 3; and pharmaceutically acceptable salts, esters, tautomers, individual isomers, and mixtures of isomers thereof.
- 4. The compound of claim 1 wherein:
R1 is
(a) phenyl, optionally substituted with one to two R3, (b) R6CH═CH—(c) C1-6alkyl, (d) —C2-3alkylOH, (e) —CF3, (f) —C1-6alkoxy, (g) —OC2-3alkylOH, (h) —C1-6alkylthio, or (i) —C(O)NHR′, wherein R′ is R6, pyridyl or —CH3; R2 is heterocyclyl wherein said heterocycle is selected from 1-piperidinyl, 1-piperazinyl, 1-azepanyl, 1,4-diazacycloheptan-1-yl and 1-azepanyl and is optionally substituted with one to three R7; R3 is chosen from —CH3, —OCH3, F, Cl, —CO2CH3, —SO2CH3 and —NO2; R4 and R5 are independently selected from H, —CH3 and benzyl; R6 is a phenyl group optionally substituted with one or two groups selected from Cl, F, C1-6alkyl, —CN, CO2C1-6alkyl, C(O)NR4R5, —SO2NH2, —NO2, —OH, —NH2, —CF3 and C1-6alkoxy or R6 is C3-6cycloalkyl, —CH2OH, naphthalene-2-yl, naphthalene-1-yl or 2-thienyl; R7 is selected from —OH, —CN, oxo, —CO2C1-6alkyl, —C(O)N(R4)(R5), —N(R4)(R5), —CH2N(R4)(R5), CH2OH, C1-6alkyl, —C(O)C1-6alkylN(R4)(R5), —NHC(O)N(R4)(R5), —S(O)nC1-6alkyl, H2NCH(R8)C(O)—, HO(CH2)mCH2CH(NH2)C(O)—, HOCH(R6)CH2NH—, R6CH2CH(OH)CH2NH—, R6OCH2CH(OH)CH2NH— and —C(O)heterocyclyl, wherein said heterocyclyl is selected from piperidinyl, piperazinyl, morpholinyl and pyrrolidinyl, or R7 is 2-hydroxyethylamino, methylcarbamimidoyl, hydroxyimino, hydrozinocarbonyl, sulfamoyl, methanesulfonylamino, methylsulfonylhydrazino, 2-hydroxypropylamino, 2,3-dihydroxypropylamino, 2-hydroxy-1-methylethylamino, carbamoylmethylamino, N′-phenylhydrazinocarbonyl or toluene-4-sulfonylamino; R8 is selected from C1-6alkyl, —(CH2)1-4NH2, phenyl or benzyl; and pharmaceutically acceptable salts, esters, tautomers, individual isomers, and mixtures of isomers thereof.
- 5. The compound of claim 4 wherein
R1 is
(a) —CH2CH2CH3, (b) —OCH2CH3, (c) —SCH3, (d) —C(O)NHR′, where R′ is 3-pyridyl, or phenyl substituted in the 4-position with —OH, —C(O)NH2, or —SO2NH2; (e) —CF3 R2 is heterocyclyl wherein said heterocycle is selected from 1-piperidinyl and 1-piperazinyl and is optionally substituted with one to three R7; R4 and R5 are independently selected from H, —CH3 and benzyl; R6 is a phenyl group optionally substituted with one or two groups selected from Cl, F, —CH3, —CN, —CO2CH3, —C(O)NR4R5, —NO2, —OH, —NH2, —CF3 and —CH3, or R6 is naphthalene-2-yl, naphthalene-1-yl or 2-thienyl; R7 is selected from —OH, —CN, oxo, —C(O)NH2, —NH2, —CH2NH2, —CH3, —NHC(O)NH2, H2NCH(R8)C(O)—, HOCH(R6)CH2NH—, R6CH2CH(OH)CH2NH— and R6OCH2CH(OH)CH2NH—, or R7 is 2-hydroxyethylamino, methylcarbamimidoyl, methanesulfonylamino, methylsulfonylhydrazino, 2-hydroxypropylamino, 2,3-dihydroxypropylamino, carbamoylmethylamino or N′-phenylhydrazinocarbonyl; R8 is —(CH2)1-4NH2; and pharmaceutically acceptable salts, esters, tautomers, individual isomers, and mixtures of isomers thereof.
- 6. A compound selected from the group consisting of:
3-Amino-6-(4-oxo-piperidin-1-yl)-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-(4-amino-4-cyano-piperidin-1-yl)-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-(4-amino-piperidin-1-yl)-4-(4-methanesulfonyl-phenyl)-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-(4-amino-piperidin-1-yl)-4-methylsulfanyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-(4-amino-piperidin-1-yl)-4-((E)-styryl)-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-(4-amino-piperidin-1-yl)-4-(4-nitro-phenyl)-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-[1,4]diazepan-1-yl-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide 3-Amino-6-[4-(2,4-diamino-butanoyl)-piperazin-1-yl]-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-(4-amino-piperidin-1-yl)-4-[(E)-2-(4-methoxy-phenyl)-vinyl]-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-(2-aminomethyl-piperidin-1-yl)4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-(4-amino-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-piperazin-1-yl-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-(4-amino-piperidin-1-yl)-4-((E)-2-p-tolyl-vinyl)-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-[4-(2,3-dihydroxy-propylamino)-piperidin-1-yl]-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-[4-(2-hydroxy-ethylamino)-piperidin-1-yl]-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-(4-amino-piperidin-1-yl)-4-((E)-2-m-tolyl-vinyl)-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-(4-methanesulfonylamino-piperidin-1-yl)-4-propyl-thieno[2,3-b]pridine-2-carboxylic acid amide; 4-[3-Amino-6-(4-amino-piperidin-1-yl)-2-carbamoyl-thieno[2,3-b]pyridin-4-yl]-benzoic acid methyl ester; 3-Amino-6-[4-(2-hydroxy-2-phenyl-ethylamino)-piperidin-1-yl]-4-propyl-thieno[2,3-b]pridine-2-carboxylic acid amide; 3-Amino-6-piperidin-4-yl-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-(4-amino-piperidin-1-yl)-4-(2,5-difluoro-phenyl)-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-[4-(N′-phenyl-hydrazinocarbonyl)-piperazin-1-yl]-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-[4-((S)-2-hydroxy-2-phenyl-ethylamino)-piperidin-1-yl]-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-[4-((R)-2-hydroxy-2-phenyl-ethylamino)-piperidin-1-yl]-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-{4-[2-hydroxy-2-(4-nitro-phenyl)-ethylamino]-piperidin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-(4-amino-piperidin-1-yl)-4-ethoxy-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-[4-((S)-2-hydroxy-propylamino)-piperidin-1-yl]-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-[4-((S)-2-hydroxy-propylamino)-piperidin-1-yl]-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-{4-[2-hydroxy-2-(3-hydroxy-phenyl)-ethylamino]-piperidin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-{4-[2-hydroxy-2-(4-hydroxy-phenyl)-ethylamino]-piperidin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-(4-amino-azepan-1-yl)-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-(4-amino-3-hydroxy-piperidin-1-yl)-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-(4-amino-piperidin-1-yl)-4-(2,4-difluoro-phenyl)-thieno[2,3-b]pridine-2-carboxylic acid amide; 3-Amino-6-(4-amino-piperidin-1-yl)-4-(4-cyano-3-fluoro-phenyl)-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-(4-amino-piperidin-1-yl)-4-isopropoxy-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-[(1H-indol-3-ylmethyl)-amino]-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-(4-hydroxy-piperidin-1-yl)-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-{4-[2-(4-amino-phenyl)-2-hydroxy-ethylamino]-piperidin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-{4-[2-hydroxy-2-(4-methoxy-phenyl)-ethylamino]-piperidin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-{4-[2-(4-chloro-phenyl)-2-hydroxy-ethylamino]-piperidin-1-yl}-4-propyl-thieno[2,3-b]pridine-2-carboxylic acid amide; 3-Amino-6-(4-hydroxy-piperidin-1-yl)-4-(4-methanesulfonyl-phenyl)-thieno[2,3-b]pyridine-2-carboxylic acid amide; 4-{2-[1-(3-Amino-2-carbamoyl-4-propyl-thieno[2,3-b]pyridin-6-yl)-piperidin-4-ylamino]-1-hydroxy-ethyl}-benzoic acid methyl ester; 3-Amino-4-(4-cyano-3-fluoro-phenyl)-6-(4-hydroxy-piperidin-1-yl)-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-4-ethoxy-6-(4-hydroxy-piperidin-1-yl)-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-4-propyl-6-(4-ureido-piperidin-1-yl)-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-((S)-3,4-dihydroxy-piperidin-1-yl)-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-(4-hydroxy-piperidin-1-yl)-4-methylsulfanyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-(4-hydroxy-piperidin-1-yl)-4-(3-hydroxy-propyl)-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-{4-[2-(4-carbamoyl-phenyl)-2-hydroxy-ethylamino]-piperidin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-(4-hydroxy-piperidin-1-yl)-thieno[2,3-b]pyridine-2,4-dicarboxylic acid 2-amide 4-pyridin-3-ylamide; 3-Amino-6-((S)-3-hydroxy-4-methanesulfonylamino-piperidin-1-yl)-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-[4-(2-hydroxy-2-naphthalen-2-yl-ethylamino)-piperidin-1-yl]-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-[4-(N′-methylsulfonyl-hydrazino)-piperidin-1-yl]-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-[4-(2-hydroxy-2-naphthalen-1-yl-ethylamino)-piperidin-1-yl]-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-{2-[1-(3-Amino-2-carbamoyl-4-propyl-thieno[2,3-b]pyridin-6-yl)-piperidin-4-ylamino]-1-hydroxy-ethyl}-benzoic acid methyl ester; 3-Amino-6-(4-amino-4-methyl-piperidin-1-yl)-4-ethoxy-thieno[2,3-b]pridine-2-carboxylic acid amide; 3-Amino-6-{4-[2-hydroxy-2-(4-methylcarbamoyl-phenyl)-ethylamino]-piperidin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-{4-[2-(4-dimethylcarbamoyl-phenyl)-2-hydroxy-ethylamino]-piperidin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-{4-[2-(4-benzylcarbamoyl-phenyl)-2-hydroxy-ethylamino]-piperidin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-{4-[2-(3-carbamoyl-phenyl)-2-hydroxy-ethylamino]-piperidin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; 3-Amino-6-(4-hydroxy-piperidin-1-yl)-thieno[2,3-b]pyridine-2,4-dicarboxylic acid 2-amide 4-[(4-hydroxy-phenyl)-amide]3-Amino-6-(4-hydroxy-piperidin-1-yl)-thieno[2,3-b]pyridine-2,4-dicarboxylic acid 2-amide 4-[(4-carbamoyl-phenyl)-amide]3-Amino-6-(4-hydroxy-cyclohexyl)-thieno[2,3-b]pyridine-2,4-dicarboxylic acid 2-amide 4-[(4-sulfamoyl-phenyl)-amide]3-Amino-6-(4-hydroxy-piperidin-1-yl)-thieno[2,3-b]pyridine-2,4-dicarboxylic acid 2-amide 4-pyridin-4-ylamide 3-Amino-6-[4-(2-hydroxy-3-phenoxy-propylamino)-piperidin-1-yl]-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide 3-Amino-6-[4-(2-hydroxy-3-phenyl-propylamino)-piperidin-1-yl]-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide 3-Amino-6-{4-[2-hydroxy-3-(4-methoxy-phenoxy)-propylamino]-piperidin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide 3-Amino-6-{4-[3-(4-carbamoyl-phenoxy)-2-hydroxy-propylamino]-piperidin-1-yl}-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide 3-Amino-6-(4-amino-3,3-dimethyl-cyclohexyl)-4-propyl-thieno[2,3-b]pyridine-2-carboxylic acid amide; and pharmaceutically acceptable salts, esters, tautomers, individual isomers, and mixtures of isomers thereof.
- 7. A method of treating inflammatory and autoimmune conditions said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound according to formula (I):
- 8. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1.
- 9. A method of treating an inflammatory or autoimmune disease condition, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound according to claim 1.
- 10. The method according to claim 9 wherein the inflammatory or autommune disease or condition is selected from the list consisting of osteoarthritis, reperfusion injury, asthma, multiple sclerosis, Guillain-Barre syndrome, Crohn's disease, ulcerative colitis, psoriasis, graft versus host disease, systemic lupus erythematosus, rheumatoid arthritis, Alzheimer's disease, toxic shock syndrome, insulin-dependent diabetes mellitis, acute and chronic pain, thermal injury, adult respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), multiple organ injury secondary to trauma, acute glomerulonephritis, dermatoses with acute inflammatory components, acute purulent meningitis or other central nervous system disorders, Grave's disease, myasthenia gravis, scleroderma and atopic dermatitis;
- 11. The method of claim 9 wherein the inflammatory or autoimmune disease is selected from osteoarthrists, rheumatoid arthritis, Chrohn's disease, ulcerative colitis, asthma, adult respiratory distress syndrome (ARDS) and chronic obstructive pulmonary disease (COPD).
- 12. A method of treating atherosclerosis, myocardial infarction or stroke, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound according to claim 1.
- 13. A method of treating cancer selected from lymphoid-, myeloid- and epithelial-derived malignancies, leukemia, lymphomas, breast cancer, gastric cancer, colorectal cancer, lung cancer, and pancreatic cancer, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound according to claim 1.
- 14. A method of making a compound of formula (I):
APPLICATION DATA
[0001] This application claims benefit to U.S. provisional application No. 60/386,312 filed Jun. 6, 2002 and U.S. provisional application No. 60/457,867, filed Mar. 26, 2003 and are hereby claimed and said applications are herein incorporated by reference.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60386312 |
Jun 2002 |
US |
|
60457867 |
Mar 2003 |
US |